Association of selected factors with long-term prognosis and mortality after dual-chamber pacemaker implant

Authors: Maciej Dębski, Mateusz Ulman, Andrzej Ząbek, Krzysztof Boczar, Kazimierz Haberka, Marcin Kuniewicz, Jacek Lelakowski, Barbara Małecka

DOI: 10.5603/CJ.a2018.0093

Article type: Original articles

Submitted: 2018-02-19

Accepted: 2018-06-18

Published online: 2018-08-24

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
Association of selected factors with long-term prognosis and mortality after dual-chamber pacemaker implant

Short title: Survival after DDD implant

Maciej Dębski¹, Mateusz Ulman¹, Andrzej Ząbek¹, Krzysztof Boczar¹, Kazimierz Haberka¹, Marcin Kuniewicz¹,², Jacek Lelakowski¹,³, Barbara Małecka¹,³

¹Department of Electrocardiology, John Paul II Hospital, Krakow, Poland
²Department of Anatomy, Jagiellonian University Medical College, Krakow, Poland
³Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

Address for correspondence: Maciej Dębski, MD, Department of Electrocardiology, John Paul II Hospital, ul. Prądnicka 80, 31–202 Kraków, Poland, tel: +48 12 614 23 81, fax: +48 12 633 23 99, e-mail: maciekdebski@gmail.com

Abstract

Background: Dual-chamber (DDD) pacing is the most widely utilised pacing modality in many parts of the world. The present study aimed to evaluate life expectancy of DDD pacemaker patients in comparison to the age- and sex-matched general population, assess changes in baseline characteristics over three decades of the inclusion period and determine the association between selected variables and patient survival.

Methods: This longitudinal study of consecutive primary DDD pacemaker implantations performed between 1984 and 2014, with all-cause mortality until 2016 as the endpoint, was conducted at a single-centre university hospital.

Results: Under assessment were 3928 patients with a total of 30,087 patient-years of survival time. Compared to the general population, the observed survival was significantly inferior until 12 years post DDD pacemaker implant (HR = 1.499, p < 0.001), whereas after 12 years of follow-up the observed survival was significantly superior (HR = 0.555, p < 0.001). A comparison of patient baseline characteristics over three decades revealed the following significant changes: more elderly patients, more female patients, less patients with atrioventricular block, more patients with atrial fibrillation/atrial flutter (AF/AFL) and fewer patients with an apical right ventricular (RV) lead position in the later decades. In multivariate analysis male sex and higher age were the only variables significantly associated with shorter
survival time. Indication for pacing, history of pre-implant AF/AFL, RV lead position and device infection were not associated with survival.

**Conclusions:** In the very-long-term follow-up of DDD pacemaker patients, the parameters associated with survival were sex and baseline age at first implantation.

**Key words:** mortality, survival, risk factors, cardiac pacing, atrial fibrillation

**Introduction**

Population-based observational studies and randomized controlled trials have assessed long-term survival and a variety of factors for their prognostic importance after pacemaker (PPM) implant. Evaluated risk factors included baseline factors such as patient gender, age at implantation, decade of implantation, type of bradyarrhythmia, presence of atrial fibrillation (AF), cardiovascular diseases, non-cardiac comorbidities and periprocedural factors such as type of pacing mode, urgency of the procedure, position of the right ventricular (RV) lead and necessity of temporary pacing [1–6]. Results have varied depending on population sample size, baseline characteristics, enrolment criteria, length of follow-up and the choice of evaluated factors. Currently, dual-chamber (DDD) pacing is by far the most widely utilized pacing modality in clinical practice in many parts of the world, and its use is exhibiting an increasing trend [7–9]. According to the 2013 European Society of Cardiology (ESC) guidelines, DDD pacing mode is the first choice in patients with sick sinus syndrome (SSS) and atrioventricular block (AVB) [10]. Despite its widespread use, the very-long-term survival of patients with DDD PPMs has not been addressed separately from other pacing modalities in an analysis of an unselected, real-world cohort. Therefore, the present aim was to examine prognostic impact of selected variables on survival time and overall mortality of the DDD PPM population compared to an age- and sex-matched population. Moreover, patient profiles and long-term survival outcomes were compared after DDD PPM implantation across three successive decades at a single center.

**Methods**

The study cohort consisted of all consecutive patients who underwent primary DDD PPM implantation between 4 October 1984 (first DDD PPM implantation) and 31 December 2014 at a high-volume, third-level reference university implantation centre. Each patient was
followed up after PPM implantation up to 31 August 2016 or the time of death before 1 September 2016. The data of patient survival status and deceased patient date of death were collected from the national death registration system. Information on death dates was available up until the end of August 2016. The endpoint was all-cause mortality. The data used in the analysis included (1) patient demographic baseline characteristics: date of birth, age at implantation and sex; (2) index arrhythmia (anti-bradycardia pacing indication): AVB defined as third-degree AVB, second-degree AVB and intraventricular conduction abnormalities (bundle branch block and/or fascicular block) with syncope or symptomatic SSS; (3) history of atrial fibrillation/atrial flutter (AF/AFL) prior to DDD PPM implantation; (4) position of the right ventricular (RV) lead: apical or non-apical at discharge from the department; (5) time of device-related infection onset and (6) date of death declared in the death certificate. This information was retrospectively gathered from paper and electronic medical records of hospitalizations when DDD PPM implantation was performed, operative reports and outpatient pacemaker clinic records. If the patients had various coexisting types of bradyarrhythmia, the following priority ranking was applied for assigning the main indication for anti-bradycardia pacing: third-degree AVB, second-degree AVB, SSS and finally intraventricular conduction abnormality (bundle branch block and/or fascicular block) with syncope in case there was no other cause of syncope. SSS was represented by sinoatrial block, sinus node arrest, tachycardia–bradycardia syndrome and chronotropic incompetence. The term ‘history of AF/AFL’ was defined as AF and/or AFL documented on electrocardiogram prior to DDD PPM implantation and included paroxysmal and persistent AF and/or AFL provided that the restoration of sinus rhythm was planned after DDD PPM implantation. Patients with permanent AF/AFL were referred for VVI PPMs throughout the study period. Device-related infection included local device infection and cardiac device-related endocarditis. The position of the RV lead was determined from operative reports and postprocedure, posteroanterior and left lateral chest radiographs.

Regarding the RV lead implantation technique, on a year-over-year basis, we specified the periods when RV apical lead fixation prevailed and when non-apical localisations were utilized more frequently. The implantation period 1984–2014 was divided into three successive time intervals referred to as decades: the first decade was from 1 October 1984 to 31 December 1994, the second was from 1 January 1995 to 31 December 2004 and the third was from 1 January 2005 to 31 December 2014. On a decade-over-decade basis, the number of patients, their baseline characteristics at the time of implantation and the type of RV lead position were compared.
Regarding survival data, the total duration between the first DDD PPM implantation and either the date of death or end of the follow-up period (31 August 2016) was calculated for the whole cohort and referred to as patient-years of survival time. Additionally, life expectancy tables provided by Central Statistical Office for Poland for years 1990–2014 to match each person in the cohort with the age- and sex-matched life expectancy predicted at the year of DDD PPM implantation were used [11]. Patients who underwent implantation between 1984 and 1989 were matched with the life expectancy predicted in 1990. The end date of follow-up which is 31 August 2016 was used to censor expected survival.

Statistical analysis

The data were evaluated using IBM SPSS Statistics for Windows, Version 25 (IBM Corp., Armonk, NY, USA). Normality was tested using Shapiro-Wilk test for samples less than or equal to 2000 and Kolmogorov-Smirnov test for samples greater than 2000. Continuous variables are expressed as mean, standard deviation (SD) and additionally as median and interquartile range (IQR) for variables with non-normal distribution. Groups were compared using the $\chi^2$ test for discrete variables and the Mann-Whitney U test for continuous variables with non-normal distribution. Event-free rates were calculated using the Kaplan-Meier analysis method and compared using the log-rank test. The associations between patient survival and the selected variables were assessed using a Cox proportional hazards model and presented as hazard ratio (HR) with 95% confidence interval (CI). The associations between patient survival and variables with time-varying effect (strength of a factor was not constant over time) and time-varying covariates (value of the factor was not constant over time) were tested using Cox model with time-dependent covariate. A p value of < 0.05 was considered statistically significant.

Results

A total of 3932 consecutive patients underwent primary DDD PPM implantation during the study period. The data of patient survival status on the last day of follow-up were available for 3928 (99.9%) patients. Four (0.1%) patients were excluded from the analysis due to unverified survival status because of unavailability of an identification number. Notably, for all baseline variables considered in the study population (3928 patients), there was no missing data.

The patient baseline clinical characteristics and a comparison of data from successive decades of DDD PPM implantation are presented in Table 1. The mean (SD) age at the time
of implantation was 69.8 (12.1, range, 15.3–96.6, median [IQR] 71.9 [14.2]) years; 53.7% of patients were male; 2610 (66.4%) patients had SSS; 1318 (33.6%) patients had AVB defined as third-degree AVB (552 patients), second-degree AVB (737 patients) and bundle branch block with syncope (28 patients). AF/AFL before implantation was observed in 1318 (33.6%) patients. Women were older than men at the time of implantation: 70.5 (11.7), (median 72.6, IQR 13.1 vs. median 69.2, IQR 12.4; median 71.2, IQR 14.8) years (p < 0.001); patients with SSS were older than those with AVB: 70.4 (11.2), (median 72.2, IQR 13.2 vs. median 68.6, IQR 13.7; median 71.3, IQR 16.1) years (p = 0.004); and patients with a history of AF/AFL were older than AF/AFL-free patients: 71.9 (10.1), (median 73, IQR 12 vs. median 68.7, IQR 12.9; median 71.2, IQR 15.2) years (p < 0.001). AVB was present in 25.6% of women and 44.4% of men (p < 0.001). The prevalence of AF/AFL before implantation reached 40.9% in women and 27.2% in men (p < 0.001). From 1984 to 2005, the majority of RV leads were placed at the RV apex, and from 2006, the majority of RV leads were placed in a non-apical position. A comparison of baseline characteristics among the three successive decades revealed a significant rise in number of procedures, average age at implantation, number of women referred for DDD PPM, prevalence of SSS and prevalence of AF/AFL prior to implantation (Table 1). Furthermore, stratification of patients by age group disclosed a significant decreasing trend in the proportion of patients before or in the seventh decade of life and an increasing trend in the proportion of patients in eighth, ninth and tenth decades of life (p < 0.001).

A total of 30,087 patient-years of survival time was calculated for 3928 patients. The mean (SD) observation time was 7.7 (5.3), (median 6.4, IQR 6.7) years. During the follow-up period 1435 (36.5%) patients died. The mean (SD) age of the deceased patients was 79.9 (9.7), (median 81.6, IQR 11.3) years. The Kaplan-Meier estimates for survival probability after DDD PPM implantation at 1, 2, 5, 10, 15 and 20 years after the procedure amounted to 96%, 92%, 82%, 62%, 46% and 32%, respectively. With regard to age- and sex-matched survival data, the predicted number of deaths amounted to 1262 (32.1%) and predicted mean (SD) observation time was 8.4 (4.6), (median 7.4, IQR 5.8) years. The expected survival curve had a reverse sigmoidal shape and crossed the observed survival at 12 years after implantation. Until 12 years of follow-up the observed risk of death was higher than expected (HR = 1.499, 95% CI 1.376–1.633, p < 0.001), whereas after 12 years observed mortality was lower than expected (HR = 0.555, 95% CI 0.468–0.658, p < 0.001) (Fig. 1). The Kaplan-Meier curves revealed no significant difference in survival with regard to index arrhythmia (AVB vs. SSS; p = 0.92) (Fig. 2A) and a history of AF/AFL before implantation (p = 0.503)
Male sex was associated with unfavourable survival ($p < 0.001$) (Fig. 2C). Patients with apical RV lead position compared to patients with non-apical lead position had a significantly better survival during the first 10 years after implantation ($p = 0.002$) (Fig. 3A). With regard to the time of implantation, the later the decade of implantation the worse survival was observed with statistically significant linear trend for factor levels ($p < 0.001$) (Fig. 4A). However, after survival adjustment for sex and age at implantation the difference in survival between apical and non-apical RV lead position group was attenuated ($p = 0.196$) (Fig. 3B). Furthermore, survival during 10 years after implantation after adjustment to sex and age was superior in patients with implantation in third decade compared to patients with implantation in second decade ($p = 0.017$). Comparing sex- and age-adjusted survival curves for first vs. second decade and first vs. third decade there were no statistically significant differences (Fig. 4B).

The Cox proportional hazard regression model demonstrated that older age at implantation and male sex were significantly associated with higher mortality. By contrast, pacing indication and a history of AF/AFL were not associated with survival (Fig. 5).

During follow-up 43 (1.1%) patients, 20 females, developed device-related infection after a mean (SD) follow-up of 7.3 (5.3), (median 7.2, IQR 8.7) years. 26 (60.4%) patients with local infections were observed and 17 (39.5%) patients with cardiac-device related infective endocarditis. Within 1 year from implantation 6 (14%) patients developed device-related infections. Death occurred in 14 (32.6%) patients, 5 females, after a mean (SD) period of 9.2 (6), (median 8.4, IQR 6.8) years from infection diagnosis. Device-related infection was not associated with an increased risk of death ($HR = 0.693$, 95% CI 0.097–4.93, $p = 0.714$).

Discussion

The long-term survival of PPM patients has been assessed in several population-based studies of general PPM populations that included from 1.5% to 73.3% patients with DDD PPM [1, 2, 4, 5, 12–14]. Importantly, no study has analysed mortality in very-long-term DDD PPM patients only, or identified independent risk factors for mortality in this population. Therefore, the present study, which had an excellent (99.9%) rate of complete data on overall survival, was designed to allow comparisons in a large group of consecutive patients enrolled without exclusion criteria who received a DDD pacemaker at a single centre and were free from permanent AF/AFL at the moment of implantation. With 3928 patients, 30,087 patient-years of survival time and an observation time of three decades, this is one of the largest
studies to reliably examine very-long-term survival in patients referred for primary DDD PPM implantation.

In reports on survival of a pacemaker population, authors have concluded that prognosis of PPM recipients without significant comorbidities at baseline approached that of the general population [1, 5, 13, 14]. Among the factors contributing most to increased mortality in the pacemaker group relative to the control population were significant non-cardiac comorbidities and structural heart disease [1, 5, 13, 14]. Pyatt et al. [4] have reported significantly higher overall mortality in pacemaker cohort compared to expected mortality during a period of 8 years after implantation. The present data, showing significantly worse overall survival in DDD cohort relative to the expected survival until 12 years after implantation are in agreement with the results of Pyatt et al. [4]. On the other hand, after 12 years post-implant survival among DDD recipients significantly exceeded survival of general population. Presumably, long-term benefit from DDD PPM beyond 12 years of follow-up might have applied predominantly to a population without significant comorbidities and were relatively young at baseline. Reasons for improved survival after 12 years, post-implant in DDD PPM patients, might have included prevention against sudden bradyarrhythmic death and regular follow-up with cardiologist which might have allowed early recognition and treatment of cardiovascular diseases.

The 1-year survival rate of the present DDD cohort was 96%. These data appear to accord with 1-year overall survival rates from 90.5% to 96% as provided in reports of DDD populations [4, 12, 15, 16] and rates from 91% to 94% as provided in reports of general PPM populations [1, 5, 13, 14]. At 5-year follow-up, cumulative survival rate was 82%. Reported 5-year survival rate of DDD cohorts was significantly lower and accounted for 58% to 64.7% [4, 12, 17], whereas in general PPM cohorts, this value reached 58.2% to 69% [2, 5, 18]. Long-term estimated survival probability at 10-year follow-up after implantation was 62%, which is broadly consistent with other reports of general PPM populations: from 44.8% to 75.4% [2, 13]. The 20-year survival probability was estimated at 32% in the present study compared with 21.4% observed by Brunner et al. [2]. Importantly, in the study Brunner et al. [2], a significant number of patients (38.6%) were lost to follow-up and censored as alive on the day of their last visit, which renders their information on estimated survival rates less accurate.

Regarding baseline characteristics, observed a higher prevalence of men across the study period was observed, which is in accordance with the majority of studies in DDD PPM populations [15–17, 19] and general PPM populations [1, 2, 5, 9, 12, 13, 18] except for
Scandinavian populations, in which the prevalence of women receiving first DDD PPM was reported to be higher than that of men [20, 21]. In the present study, the prevalence of men exhibited a statistically significant decreasing trend from 58% in the first decade to 52% in the third decade, which is opposed to observations of a stable proportion of men in successive eras of PPM implantation [1, 2]. The age of patients at first PPM implantation increased with each decade, similar to a trend observed in western countries [2, 7, 18]. Furthermore, the present study identified a significant increase in PPM utilisation among older patients (> 70 years). In countries with advanced health systems, the percentage of PPM recipients older than 80 years was >30% and exhibited a significantly increasing trend [1, 8, 9, 18]. Female patients were older than men at the time of implantation, as it has been observed in a majority of countries [1, 2, 8, 22], and were more likely to present with SSS [1, 2, 22]. There has been a shift in the main indications, with AVB being more prevalent in 1984–1994 and the domination of SSS in 1995–2014. Unlike the results herein, a higher incidence of high-grade AVB than of SSS throughout the study period has been frequently reported in general PPM populations [1, 2, 4, 5, 9, 12–14, 18]. Importantly, in the present study, the prevalence of pre-implant AF/AFL soared across the study period, reaching 39% in the third decade, a trend that can probably be attributed to enhanced detection of AF/AFL, increasing age of patients [23] and shift of indications towards SSS [20, 24].

The significant association between male sex and older age at baseline and worse survival has been noted previously [1, 2, 4, 5, 13] and corresponds to the fact that women generally have a longer life expectancy. As expected, the present study demonstrated that in the Cox regression model, age and male sex were independently associated with mortality after primary DDD implantation. For each additional year of age at implantation, a 7.8% increase in mean risk of death was observed; in the general PPM population, this value has been reported as 5% to 9% [2, 4, 5, 12]. By contrast, no significant difference in survival with regard to either index arrhythmia or a history of AF/AFL was detected in the present study. The literature on the influence of index arrhythmia on survival comprises conflicting results. In a multivariate analysis of the study population, Brunner et al. observed that SSS was associated with better survival than was AVB; however, on considering patients with first implantation during the last decade (1991–2000), this effect was no longer significant [2]. Furthermore, Jahangir et al. and Pyatt et al. have identified that AVB is a risk factor for increased mortality compared with SSS [4, 12]. Conversely, Udo et al. [5], Mayosi et al. [13] and Jelić et al. [14] have demonstrated that survival of SSS and AVB patients is comparable.
In the FOLLOWPACE study, a history of atrial tachyarrhythmia was not an independent predictor of survival [5]. Conversely, Bradshaw et al. [1] demonstrated that a history of AF was significantly associated with reduced 1-year and 5-year survival. Of note, with increasing patient age at implantation across the second and third decades, age- and sex-adjusted survival of patients displayed an improving trend. The available data indicate that either the later the first implantation occurs in the study period, the better the prognosis of the PPM recipient [2] or that there is no association between the era of implantation and mortality [1]. Regarding the RV lead position, after adjustment for sex and age at implantation there was no significant association with mortality. Witt et al. [6] assessed 3450 unselected patients who underwent DDD PPM implantation between 2004 and 2014, among whom the RV lead was positioned at the RV apex in the majority of patients (71.9%) and less commonly at the septum (6.9%) or other RV regions (21.2%). Authors reported that an apical RV lead position was associated with increased mortality compared with a septal position group (31% vs. 24%, \( p = 0.02 \)). Patients with very high levels of pacing, greater than 90%, had a significantly lower mortality rate in the septal pacing group (16% vs. 31%, \( p = 0.03 \)), whereas patients with very low levels of pacing, less than 10%, did not have a significant difference in mortality (13% vs. 23%, \( p = 0.10 \)) [6]. Due to the retrospective design of the present study and the findings of Witt et al. [6], none of the aforementioned results can be taken as a definitive answer to the long-debated question of whether an apical position of the RV pacing lead is worse than a non-apical position.

In the present study, an infection rate of 1.1% per patient was observed, which is in line with previous reports from literature. Hercé et al. [25] in a study based on a registry which included 2496 patients observed 35 (1.4%) cases with device-related infections. Greenspon et al. [26] reported that the rate of device-associated infections in the United States rose from 1.53% in 2004 to 2.41% in 2008, likely due to an increase of patients with multiple comorbidities. Earlier reports on DDD pacemaker population with implantation between 1984–2002 showed the rate of device-related infection was less than or equal to 1.2% [27, 28]. The present study shows that device-related infection was not a risk factor for increased mortality during follow-up and patients diagnosed with pacing system infection had relatively good long-term survival. Results herein, are in keeping with the findings of a prospective matched cohort-study of Deharo et al. [29] who observed no significant excess in all-cause long-term mortality in infection cohort compared with controls without device-related infection.
Limitations of the study

The main limitation is the retrospective nature of this study, with all its inherent limitations. First, data regarding other baseline factors that possibly influenced survival, such as a history of concomitant diseases, medications, functional status (New York Heart Association class) and urgency of the procedure (elective/emergency), were not complete for the whole population and were therefore not included in the analysis. Similarly, the percentage of RV pacing was not available for all patients, therefore the association between RV lead position and mortality could not be further analyzed in subgroups with different requirements of RV pacing. Second, the prevalence of pre-implant AF/AFL in the first two decades may have been underrated due to lower awareness and surveillance. Third, selection bias of presumably ‘sicker’ patients with AVB referred for single-chamber ventricular pacing could not be excluded and presumably ‘healthier’ patients with SSS to single-chamber atrial pacing because evidence supporting the use of DDD systems as a first-choice pacing mode for both indications was unavailable at the time.

Conclusions

With an increasing number of DDD PPM implantations over time, a significant change in patient baseline characteristics was observed: average age at implantation continued to rise, more women were referred for implantation and the prevalence of AF/AFL prior to implantation grew rapidly. During 12 years after implantation, survival of the DDD cohort was significantly worse than in an age- and sex-matched general population, however, after 12 years the survival of DDD recipients were significantly better than expected. Male sex and age were the only clinical variables associated with a shortened survival time and an increased probability of death. Indication for pacing, history of pre-implant AF/AFL, RV lead position and device-related infection were not associated with survival.

Conflict of interest: None declared

References


Table 1. Comparison of the patient baseline characteristics across three successive decades of DDD pacemaker implantations.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>3928</td>
<td>210 (5.3%)</td>
<td>1144 (29.1%)</td>
<td>2574 (65.5%)</td>
<td></td>
</tr>
<tr>
<td>Age [years]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–50</td>
<td>290 ± 7.4</td>
<td>41 ± 19.5</td>
<td>135 ± 11.8</td>
<td>114 ± 4.4</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>51–70</td>
<td>1537 ± 39.1</td>
<td>127 ± 60.5</td>
<td>531 ± 46.4</td>
<td>879 ± 34.1</td>
<td></td>
</tr>
<tr>
<td>71–80</td>
<td>1498 ± 38.1</td>
<td>33 ± 16.7</td>
<td>400 ± 35.0</td>
<td>1065 ± 41.4</td>
<td></td>
</tr>
<tr>
<td>81–90</td>
<td>576 ± 14.7</td>
<td>8 ± 3.8</td>
<td>76 ± 6.6</td>
<td>492 ± 19.1</td>
<td></td>
</tr>
<tr>
<td>&gt; 90</td>
<td>27 ± 0.7</td>
<td>1 ± 0.5</td>
<td>2 ± 0.2</td>
<td>24 ± 0.9</td>
<td></td>
</tr>
<tr>
<td>Mean age at implantation [years]</td>
<td>69.8 ± 12.1</td>
<td>61.0 ± 13.5</td>
<td>66.5 ± 12.0</td>
<td>72.0 ± 11.3</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Female sex</td>
<td>1817 (46.3%)</td>
<td>88 (41.9%)</td>
<td>502 (43.9%)</td>
<td>1227 (47.7%)</td>
<td>0.045</td>
</tr>
<tr>
<td>Atrioventricular block</td>
<td>1318 (33.6%)</td>
<td>113 (53.8%)</td>
<td>296 (25.9%)</td>
<td>909 (35.3%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sick sinus syndrome</td>
<td>2610 (66.4%)</td>
<td>97 (46.2%)</td>
<td>848 (74.1%)</td>
<td>1665 (64.7%)</td>
<td></td>
</tr>
<tr>
<td>History of atrial fibrillation/atrial flutter</td>
<td>1318 (33.6%)</td>
<td>22 (10.5%)</td>
<td>299 (26.1%)</td>
<td>997 (38.7%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Right ventricular lead apical position</td>
<td>1693 (43.1%)</td>
<td>210 (100%)</td>
<td>1107 (96.8%)</td>
<td>376 (14.6%)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>
FIGURE LEGEND

Figure 1. Survival of patients with DDD pacemaker relative to the age- and sex-matched general population.

Figure 2. Survival of patients with atrioventricular block relative to patients with sick sinus syndrome (A), survival of patients with a history of atrial fibrillation/atrial flutter (AF/AFL) relative to patients without pre-implant AF/AFL (B), survival of women relative to men (C).

Figure 3. Survival during 10 years after implantation in patients with right ventricular (RV) lead in apical position relative to patients with RV lead in non-apical position (A), survival after adjustment for age and sex (B).

Figure 4. Survival during 10 years after implantation according to the decade of implantation (A), survival after adjustment for age and sex (B).

Figure 5. Factors associated with survival in multivariable Cox regression model.
observed vs. expected survival up to 12 years:
HR = 1.499 (95% CI, 1.376 - 1.633) P < 0.001

observed vs. expected survival after 12 years:
HR = 0.555 (95% CI, 0.468 - 0.658) P < 0.001

Cumulative survival [%]

years after implant
Cumulative survival [%] vs. years after implantation for RV lead placement at apical versus non-apical positions. The graph shows a significant difference in cumulative survival rates, with a p-value of 0.002.